ライフサイエンスコーパス: lymph node metastases

1 s) after a previous clearance of more than 5 lymph node metastases.

2 y, including some patients with common iliac lymph node metastases.

3 1 PCa patient with proven iliac and inguinal lymph node metastases.

4 more tumor cells inside lymphatics, and more lymph node metastases.

5 rimary tumors, along with liver and draining lymph node metastases.

6 both with (P = 0.006) and without (P = 0.03) lymph node metastases.

7 in situ, and general loss of Nuc-pYStat5 in lymph node metastases.

8 ease or higher and, especially, locoregional lymph node metastases.

9 that fatal, distant metastases are seeded by lymph node metastases.

10 s as a result of local invasion and regional lymph node metastases.

11 stic variables than tumor stage or number of lymph node metastases.

12 ocarcinoma (EAC) given the low likelihood of lymph node metastases.

13 ing five matched pairs of primary tumors and lymph node metastases.

14 or cell nuclei in various gastric tumors and lymph node metastases.

15 t carcinomas and is associated with axillary lymph node metastases.

16 omarker and therapeutic target in ESCCs with lymph node metastases.

17 nd prognosis of melanoma patients with early lymph node metastases.

18 ns, including 55 primary tumors and 9 pelvic lymph node metastases.

19 h disease progression and a higher number of lymph node metastases.

20 minin 5 gamma 2 chain domain III fragment in lymph node metastases.

21 observed in distant organs in the absence of lymph node metastases.

22 -fold) but also the fraction of animals with lymph node metastases.

23 CIS), 18 invasive breast carcinomas, and two lymph node metastases.

24 s recovered from breast cancer patients with lymph node metastases.

25 f which were associated with the presence of lymph node metastases.

26 mor burden, as well as decreases in regional lymph node metastases.

27 an also make it difficult to detect axillary lymph node metastases.

28 anase expression is associated with sentinel lymph node metastases.

29 t invasive cancer at the margin, and 54% had lymph node metastases.

30 ee subtypes, one of which also included most lymph node metastases.

31 cinomas, in the lymphovascular space, and in lymph node metastases.

32 n of these genes in malignant cell lines and lymph node metastases.

33 only in invasive breast carcinomas and their lymph node metastases.

34 -M expression, and a propensity for regional lymph node metastases.

35 cluster in malignant prostate cell lines and lymph node metastases.

36 tumor showed a decrease in the corresponding lymph node metastases.

37 supraclavicular region is a common site for lymph node metastases.

38 erate to poor histologic grade, and positive lymph node metastases.

39 ely correlated with the presence of axillary lymph node metastases.

40 melanoma who are at risk for occult regional lymph node metastases.

41 Eleven patients had pathologic evidence of lymph node metastases.

42 , and age were independently associated with lymph node metastases.

43 ables independently associated with axillary lymph node metastases.

44 ive, early-stage breast cancer without overt lymph node metastases.

45 , but had fewer (2.9%, versus 16.7% in DGCs) lymph node metastases.

46 than age 45 years does not include cervical lymph node metastases.

47 lumes of interest in all visually detectable lymph node metastases.

48 e metastases and better for the detection of lymph node metastases.

49 pared with normal tissues, primary tumors or lymph node metastases.

50 (TNBC) cells, both in primary tumors and in lymph node metastases.

51 ted between primary tumors and corresponding lymph node metastases.

52 abolism between the primary PDTX and distant lymph node metastases.

53 Positive SNs were detected in 1 patient with lymph node metastases.

54 nomogram to estimate the individual risk of lymph node metastases.

55 transitional cells may be the source of the lymph node metastases.

56 tion patterns in primary PC foci and matched lymph node metastases.

57 that correlates with increased frequency of lymph node metastases.

58 s should respect the presented topography of lymph node metastases.

59 ronment, leading to widespread pulmonary and lymph-node metastases.

60 nsion and positive surgical margins, but not lymph-node metastases.

61 aging modality or technique for diagnosis of lymph-node metastases.

62 sion or (ii) extrahepatic (adrenal/bone/lung/lymph node) metastases.

63 imaging for assessment of tumor margins and (lymph node) metastases.

64 s were absent in bone metastases and rare in lymph nodes metastases.

65 erns were observed for mean (SD) nonsentinel lymph node metastases: 0.48 (1.30) for no ENE vs 1.91 (2

66 Plasma TGF-beta(1) levels in patients with lymph node metastases (14.2 +/- 2.6 ng/mL) and bone meta

67 Thirty-five patients had lymph node metastases, 19 only in the SLN.

68 patients with melanoma with palpable, proven lymph node metastases (2003-2008) referred for examinati

69 metrial invasion (20 mL) and the presence of lymph node metastases (30 mL) yielded odds ratios of 7.8

70 hout lymph node metastases versus those with lymph node metastases (78% versus 48%, P = 0.0137).

71 g was more accurate than CT for detection of lymph node metastases (A(z) = 0.76 vs 0.57, P =.04).

72 As lymph node metastases accurately predict poor disease ou

73 Lymph node metastases affect management and prognosis of

74 ast pCR and 100% had no evidence of axillary lymph node metastases after NCT.

75 ncorporate distribution as well as number of lymph node metastases after preoperative chemoradiothera

76 tients after complete dissection of regional lymph node metastases (AJCC stage III), with 28 of 55 pa

77 Relatively distant lymph node metastases along the celiac axis and/or the p

78 untreated or recurrent cervical cancers and lymph node metastases, although the excreted FDG in the

79 A proportion will present or recur with lymph node metastases (American Joint Committee on Cance

80 l disease (a liver mass, hepatic metastases, lymph node metastases, an aortic dissection, and a pheoc

81 involved was two for patients with proximal lymph node metastases and 1.5 for patients with mesorect

82 airs from 13 HNSCC patients with synchronous lymph node metastases and 10 patients with metachronous

83 d as benign 6 of 11 lesions considered to be lymph node metastases and 11 of 15 lesions considered to

84 ide and cisplatin for pulmonary and thoracic lymph node metastases and a rising serum alpha-fetoprote

85 vels of the four HOX clusters were examined, lymph node metastases and cell lines derived from lymph

86 f mortality when diagnosed in the absence of lymph node metastases and distant metastases, as shown e

87 with 5-aza also prevented the development of lymph node metastases and dramatically extended survival

88 ignificantly associated with the presence of lymph node metastases and invasive tumor stages.

89 Patients with small lymph node metastases and local recurrence were not excl

90 ation is based on number and not location of lymph node metastases and may understage disease after c

91 Lymph node metastases and not pathologic response to che

92 e the association of OS with the presence of lymph node metastases and number of metastatic nodes.

93 cosa is associated with a high likelihood of lymph node metastases and requires lymphadenectomy.

94 an increased risk of submucosal invasion and lymph node metastases and should be factored into the de

95 ensive disease (extrathyroidal extension and lymph node metastases) and those who are more likely to

96 % had a duodenal gastrinoma, 65% and 71% had lymph node metastases, and 0% and 12% had liver metastas

97 erexpressed in 35% of primary tumors, 30% of lymph node metastases, and 70% of recurrences in contras

98 be associated with extrathyroidal extension, lymph node metastases, and advanced stage in two meta-an

99 -DCFPyL and (18)F-PSMA-1007 for local tumor, lymph node metastases, and bone metastases.

100 o primary tumor size, location, frequency of lymph node metastases, and disease-specific and disease-

101 cal aggressiveness (triple-negative cancers, lymph node metastases, and distant metastases) of small-

102 igher grade tumor, an increased incidence of lymph node metastases, and elevated risk of distant recu

103 ted to deep myometrial invasion, presence of lymph node metastases, and high histologic grade (P < 0.

104 regional (P = 0.002) and distant (P = 0.012) lymph node metastases, and higher relapse rate (P < 0.00

105 ologic grade, tumor hormone receptor status, lymph node metastases, and patient age and condition at

106 Total RNA from 21 ILCs, 38 IDCs, two lymph node metastases, and three normal tissues were amp

107 , extent, and type of an invasive component, lymph node metastases, and vascular invasion.

108 on than does unenhanced MRI for detection of lymph-node metastases, and allows functional and anatomi

109 a significant increase in the prevalence of lymph node metastases,and there is no "safe" level of in

110 Our results suggest that cervical lymph node metastases are associated with compromised su

111 Lateral lymph node metastases are associated with locoregional r

112 retrospective studies suggest that regional lymph node metastases are associated with tumor recurren

113 technologies for the clinical assessment of lymph node metastases are based on the detection of canc

114 0 (N1), 11 to 20 (N2), and more than 20 (N3) lymph node metastases are important prognostic classifie

115 Axillary lymph node metastases are most significantly related to

116 A systematic review has shown that lymph node metastases are rare ( approximately 2%) with

117 Cervical lymph node metastases are recognized as a prognostic ind

118 um levels required for efficient blockade of lymph node metastases are strictly dependent on the VEGF

119 Lymph node metastases are the most significant prognosti

120 Lymph node metastases are the most significant prognosti

121 d observational analyses suggest that occult lymph-node metastases are an important prognostic factor

122 Treatment after the formation of lymph node metastases arrests the metastatic process wit

123 Increased levels of EPO and EPOR in lymph node metastases as compared to primary tumors from

124 ijacked by cancer cells to establish initial lymph node metastases, as well as by infectious agents a

125 nuclear level of DNAJB6 and the presence of lymph node metastases at diagnosis could be used to stra

126 history of bilateral orchiectomies, regional lymph node metastases at diagnosis, prior prostatectomy,

127 n level before reoperation and the number of lymph node metastases at reoperation and biochemical cur

128 Patients with lymph node metastases at the time of diagnosis had an in

129 ration depth correlates with the rate of the lymph node metastases, but a clear watershed between dee

130 igh sensitivity and specificity in depicting lymph node metastases, but guidelines have not yet been

131 1% to 3% reduction in recurrence of axillary lymph node metastases, but is associated with a 14% risk

132 scriptional cluster, including cutaneous and lymph node metastases, but not the type II cluster, not

133 patients with oral cancer and no evidence of lymph node metastases by clinical examination or CT/MRI

134 cell-based immunotherapies, to: (i) prevent lymph node metastases by redistributing cytotoxic NK cel

135 platin-based chemotherapy, and it eliminated lymph node metastases by targeting CSCs and the tumor bu

136 e, SPECT/CT allowed the identification of 11 lymph node metastases classified as thyroid remnant or a

137 ificantly higher Sec62 levels in tumors with lymph node metastases compared with nonmetastatic tumors

138 (Tnc), in primary lung tumors and associated lymph node metastases compared with normal tissue.

139 tatic cells, such as miR23b, were reduced in lymph node metastases compared with patient-matched prim

140 as maintained and in many cases increased in lymph node metastases compared with primary tumors.

141 atients with lymphatic invasion had axillary lymph node metastases, compared with 19% of the 669 pati

142 le used as a contrast agent for diagnosis of lymph-node metastases, compared with that of unenhanced

143 The majority of bone and lymph node metastases contained cells that were immunost

144 -FDG PET/CT and (18)F-FDG PET/MR imaging for lymph node metastases detection (P = 0.48).

145 eatment for a leg melanoma with duodenal and lymph nodes metastases developed a sudden bilateral visu

146 dies indicate a relatively high incidence of lymph node metastases, distant metastases, and persisten

147 les the direct PET visualization of sentinel lymph node metastases, eliminating the need for invasive

148 imaging has shown promise in helping detect lymph node metastases, even in small (subcentimeter) nod

149 node metastases and cell lines derived from lymph node metastases exhibited very similar patterns, p

150 d minimal PKR immunoreactivity, but melanoma lymph node metastases expressed a high level of PKR prot

151 aim of this study was to define the risk of lymph node metastases for intramucosal and submucosal (T

152 RI is sensitive and specific in detection of lymph-node metastases for various tumours.

153 gastric cancers of 113 patients and matched lymph node metastases from 61 of these patients.

154 hemical analyses of primary ESCC samples and lymph node metastases from a cohort of 160 patients who

155 flutamide or bicalutamide, or by excision of lymph node metastases from hormone-naive patients.

156 ul responses in patients with bulky regional lymph node metastases from penile cancer.

157 pendent patients as well as associating five lymph node metastases from the original patient set with

158 le to help differentiate even small melanoma lymph node metastases from the other lymphadenopathies (

159 It disappeared once more than 5 lymph node metastases had been cleared at other hospital

160 Pancreatic ductal adenocarcinomas with lymph node metastases had significantly greater activity

161 ment along major supplying vessels (proximal lymph node metastases) had a significantly higher rate o

162 sis that the presence and number of cervical lymph node metastases have an adverse impact on overall

163 [HR], 1.94; 95% CI, 1.11 to 3.39; P = .0209; lymph node metastases: HR, 3.63; 95% CI, 1.88 to 7.0; P

164 Sixty percent of individuals had regional lymph node metastases identified primarily in proximity

165 e (124)I-negative but (131)I-positive, and 2 lymph node metastases in 2 patients were (131)I-negative

166 ogeneous EGFR amplification in primary tumor/lymph node metastases in 4 of 14 cases, despite uniform

167 FDG PET detected lymph node metastases in 6 (86%) of 7 patients with know

168 ximal duodenum, and associated with regional lymph node metastases in 60%.

169 ents with unilateral intrathyroid tumors had lymph node metastases in 81% of central node dissections

170 (18)F-FDG PET/CT can identify lymph node metastases in a segment of patients with oral

171 ies will be needed to allow the detection of lymph node metastases in an individual patient.

172 tion of both tumor growth and development of lymph node metastases in both androgen-sensitive and and

173 The role of lymph node metastases in distant prostate cancer dissemi

174 or preoperatively evaluating the presence of lymph node metastases in endometrial carcinoma patients.

175 nd appears to be more sensitive in detecting lymph node metastases in lower lobe and hilar NSCLC comp

176 aging enables noninvasive detection of small lymph node metastases in normal-sized nodes in a substan

177 y reported as predictive for the presence of lymph node metastases in OSCC and OPSCC, was first re-ev

178 an insensitive indicator of occult regional lymph node metastases in patients with melanoma because

179 Risk of lymph node metastases in patients with pancreatic neuroe

180 The detection of occult lymph node metastases in patients with pT3N0 prostate ca

181 iously been used with great success to image lymph node metastases in prostate cancer patients.

182 The prevalence of lymph node metastases in SCC, AEG, and GC was 7%, 0%, an

183 Detection of lymph node metastases in the upper mediastinum and aroun

184 to have a clear understanding of the risk of lymph node metastases in these patients.

185 ependent tumor growth in vitro and increased lymph node metastases in vivo.

186 etection of small and otherwise undetectable lymph-node metastases in patients with prostate cancer.

187 Accurate detection of lymph-node metastases in prostate cancer is an essential

188 ted with somatic TP53 mutations and regional lymph-node metastases in sporadic breast cancer but not

189 oxide (USPIO), may enhance the detection of lymph node metastases independent of node size.

190 colorectal cancers that was associated with lymph-node metastases (INHBB, AXL, FGFR1, and PDFGRB) an

191 s were true-negative in the patients with no lymph node metastases (interpreted as grade 0 or 1 by PE

192 Location of lymph node metastases is an independent predictor for su

193 Knowledge of the risk of lymph node metastases is critical to planning therapy fo

194 The detection of regional lymph node metastases is important in cancer staging as

195 Presence or absence of lymph node metastases is the most powerful predictor of

196 ore, aggressive surgical therapy of regional lymph node metastases is warranted, and each individual'

197 nectomy (LM/SL) for identification of occult lymph node metastases is well established in primary mel

198 he response rates were 63%, 88%, and 90% for lymph node metastases (LMs), pulmonary metastases, and T

199 on in thirds has shown an increasing rate of lymph node metastases (LNM) according to the depth of wa

200 Histopathological assessment of lymph node metastases (LNM) depends on subjective analys

201 DG PET/CT for the preoperative assessment of lymph node metastases (LNM) in endometrial cancer patien

202 th morphologic imaging for the assessment of lymph node metastases (LNM) in patients with recurrent p

203 investigated in human primary PCa (n = 90), lymph node metastases (LNMs; n = 8), and benign prostati

204 g T cell subsets was associated with skin or lymph node metastases, loss of CXCR4, CXCR5, and CCR9 co

205 By MVA, only lymph node metastases, major perioperative complications

206 itive primary tumors; it was not detected in lymph node metastases matched to BRAF mutation-negative

207 BRAF mutation was detected in 20 of 26 (77%) lymph node metastases matched to BRAF mutation-positive

208 Patients with axillary lymph node metastases may benefit from postmastectomy ra

209 e prediction of deep myometrial invasion and lymph node metastases may increase diagnostic accuracy a

210 Collectively, this comparison suggests that lymph node metastases may not be an intermediate develop

211 racteristics of primary tumors predictive of lymph node metastases may prompt a more extensive surgic

212 Primary tumors (n = 43), local lymph node metastases (n = 74), and distant metastases (

213 64 months), we investigated the influence of lymph node metastases (N+), tumor infiltration depth, tu

214 criptomes (n=382), survival data (n=530) and lymph node metastases (n=100) in lung cancer patients id

215 Lateral pelvic lymph-node metastases occur in 10-25% of patients with r

216 es (P < 0.01) in vitro, as well as popliteal lymph node metastases of ESCC cells in nude mice (P = 0.

217 PLIN downregulation was also demonstrated in lymph node metastases of human solid tumors including PC

218 okinase-derived peptide (A6) in reducing the lymph node metastases of prostate cancer using a model i

219 The impact of these distant lymph node metastases on survival remains unclear.

220 ed to the mucosa, the reported prevalence of lymph node metastases once the tumor infiltrates the sub

221 e treated with a scrambled peptide developed lymph node metastases, only 22 to 25% of A6-treated mice

222 ded with time, in all 6 patients with either lymph node metastases or recurrent prostate bed carcinom

223 nce observer was low for number of organ and lymph node metastases (organ: ICC, 0.84; 95%CI, 0.77-0.8

224 d was found to be significantly decreased in lymph node metastases over paired primary tumors.

225 Lymph node metastases (P < 0.001), lymphovascular invasi

226 ted deep myometrial invasion (P < 0.015) and lymph node metastases (P < 0.025) after adjustment for p

227 Advanced T stage (P = .02), lymph node metastases (P = .004), and vascular space inv

228 nuclear level of DNAJB6 and the presence of lymph node metastases (P = .022; Pearson chi(2) test).

229 M6 expression was associated with absence of lymph node metastases (P = 0.012), lower disease stage (

230 ter methylation and the presence of regional lymph node metastases (P = 0.03).

231 = 0.0453) and borderline with the absence of lymph node metastases (p = 0.0571) and tumor proliferati

232 = 0.0238) and borderline with the absence of lymph node metastases (p = 0.0632).

233 the robust association of this profile with lymph node metastases (P = 7.3(-13)) and overall surviva

234 Conventional pathologic features (lymph node metastases, positive resection margin, poor g

235 Lymph node metastases, predominantly subtype-3, displaye

236 levels before reoperation and the number of lymph node metastases previously removed at outside faci

237 lymph node, presence or absence of sentinel lymph node metastases, primary tumor characteristics, di

238 emoval of 0 (r = 0.74 and 77%-0%) and 1 to 5 lymph node metastases (r = 0.61 and 60%-0%) elsewhere.

239 at PFKFB3 expression is highest in stage III lymph node metastases relative to normal breast tissues

240 f Syk expression were observed in tumors and lymph node metastases relative to normal tissues.

241 Immunohistochemically detected occult lymph-node metastases remained an independent and highly

242 ents) after previous removal of 0 and 1 to 5 lymph node metastases, respectively.

243 , which would have missed 51.9% and 74.1% of lymph node metastases, respectively.

244 Risk estimation for lymph node metastases should not be based on depth of tu

245 Location of lymph node metastases should therefore be considered in

246 survival is lower for patients with regional lymph node metastases suggesting that a more systematic

247 tein E-cadherin was significant decreased in lymph node metastases, suggesting PRC2 promotes epitheli

248 With regional lymph node metastases, survival drops to 45-60%, and wit

249 ation and the previous removal of 5 or fewer lymph node metastases, systematic lymph node dissection

250 d tumor pairs in HNSCC, we found synchronous lymph node metastases to be genetically more similar to

251 ents with nonmetastatic CaP to patients with lymph node metastases to patients with skeletal metastas

252 r overall survival of patients with sentinel lymph node metastases treated with breast-conserving the

253 te multiple primaries and a 70% incidence of lymph node metastases, tumor can be removed with no deat

254 tudy population was limited to patients with lymph node metastases, tumors 4 cm or larger, or local e

255 ell as 41 normal prostate specimens and nine lymph node metastases, using cDNA microarrays containing

256 Sensitivity for detecting mediastinal lymph node metastases, using pathologic confirmation and

257 as significantly higher for patients without lymph node metastases versus those with lymph node metas

258 umor cell implantation were established from lymph node metastases via in vivo selection.

259 The incidence of regional lymph node metastases was 33%.

260 The presence of occult lymph node metastases was an independent predictor of re

261 LOH on 3p and 5q in the lymph node metastases was associated significantly with

262 The rate of axillary lymph node metastases was consistent with SLN tumor load

263 The prevalence of lymph node metastases was correlated with tumor size, de

264 On multivariate analysis, location of lymph node metastases was independently associated with

265 tivariate analysis, the presence of regional lymph node metastases was the only factor associated wit

266 acy of (18)F-FDG PET/CT for the detection of lymph node metastases were 77%-85%, 91%-96%, and 89%-93%

267 r asymptomatic; without visceral disease but lymph node metastases were allowed).

268 Lymph node metastases were also significantly associated

269 that included p21 and pRB/p16, only p21 and lymph node metastases were associated with bladder cance

270 3 with p21 or p53 with pRB/p16, only p53 and lymph node metastases were associated with bladder cance

271 for predicting deep myometrial invasion and lymph node metastases were calculated.

272 Recently, it was questioned whether lymph node metastases were capable of metastasizing and

273 Occult lymph node metastases were categorized by pattern of sta

274 Lymph node metastases were detected in 37 patients (31%)

275 Analyzed according to hemipelvis, lymph node metastases were detected with histopathologic

276 In SCC, lymph node metastases were found from the neck to the ce

277 Renal lymph node metastases were found in 15.8% of the animals

278 Eighty-eight lymph node metastases were found in 33 of 120 patients (

279 entification of deep myometrial invasion and lymph node metastases were generated, and MTV cutoffs fo

280 viewed, and the prevalence and topography of lymph node metastases were identified.

281 ents with PC at intermediate or high risk of lymph node metastases were included.

282 ortantly, although paired primary tumors and lymph node metastases were largely homogeneous for relev

283 On univariate analysis, high TRG and lymph node metastases were negatively related to surviva

284 Lymph node metastases were predicted using size criteria

285 Lymph node metastases were present in 10 axillary region

286 Lymph node metastases were present in 19% of cases and 2

287 poradic groups (P = 0.95), respectively, and lymph node metastases were present in 43% and 30% of cas

288 Lymph node metastases were rare (1.3%) with intramucosal

289 ne metastasis, plotted against the number of lymph node metastases, were similar.

290 r lost in primary tumors and, in particular, lymph node metastases when compared with that in normal

291 rmed in cervical cancer patients with pelvic lymph node metastases, where we found v(0) to be higher

292 produced rapidly growing tumors and regional lymph node metastases, whereas PC-3M-IFN-beta cells did

293 tatic adenocarcinoma with readily detectable lymph node metastases, whereas single models with each o

294 related with Gleason score and occurrence of lymph node metastases while little or no Runx2 phosphory

295 Patients with lymph node metastases who underwent 18F-FDG PET/CT > or

296 iews 75 T1a and 51 T1b tumors and correlates lymph node metastases with depth of tumor invasion, tumo

297 greatest efficacy in confirming celiac axis lymph node metastases with more than 90% accuracy.

298 the sensitivity of MRI in the prediction of lymph node metastases, with no loss of specificity.

299 ses, we recently found that TRAIL-R inhibits lymph node metastases without affecting primary tumor fo

300 ed CTGF-dependent tumor growth and inhibited lymph node metastases without any toxicity observed in n